餐后奥美拉唑与吡咯替尼药物相互作用临床研究
结果显示,联合奥美拉唑后吡咯替尼的AUC0-t、AUC0-∞和Cmax几何均值比分别为0.94、0.94和0.91,均无显著差异,提示奥美拉唑不影响吡咯替尼的PK特性,且联合用药安全性良好。
要点
- 奥美拉唑不影响餐后吡咯替尼的暴露、消除、半衰期和表观清除率。
- 吡咯替尼单药与联用奥美拉唑的AUC和Cmax几何均值比无显著差异。
- 联合用药期间不良事件发生率较高,但整体安全性可控。
核心结论
- 奥美拉唑未显著影响吡咯替尼的药代动力学特性,联合用药安全性良好。
研究设计与样本
- 吡咯替尼400 mg口服于标准餐后30分钟给药,奥美拉唑从第6天至第10天口服40 mg。
主要发现
- 吡咯替尼单药与联用奥美拉唑的AUC0-t、AUC0-∞和Cmax几何均值比(90%CI)分别为0.94(0.82, 1.08)、0.94(0.83, 1.08)和0.91(0.806, 1.038)。
- 单药治疗期和奥美拉唑给药期各有6名受试者(33.3%)报告8例不良事件,联合给药期有10名受试者(55.6%)报告34例不良事件。
临床怎么用
- 临床可考虑餐后联合使用奥美拉唑与吡咯替尼,无需因PK相互作用调整剂量。
局限性
- 研究为单剂量设计,未评估多次给药后的稳态PK。
- 研究对象为健康志愿者,结论需在患者人群中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: We aimed to investigate the effect of omeprazole on the pharmacokinetics (PK) of pyrotinib and determine the safety of this combination in healthy Chinese volunteers. METHODS: Eighteen healthy volunteers were enrolled in this single-dose and self-controlled study. Pyrotinib (400 mg per oral) was administered 30 minutes after the standard meal. Omeprazole was administered from day 6 (D6) to D10 (40 mg, per oral). On D10, the subjects took omeprazole under fasting conditions, followed by pyrotinib 30 minutes after the standard meal. Blood samples for PK analyses in each phase were collected for analysing the drug concentration. Safety was assessed via clinical laboratory tests and physical examinations. RESULTS: Compared with a single dose of pyrotinib, pyrotinib coadministered with omeprazole showed no significant difference in exposure, elimination, half-life and apparent clearance rate. The mixed-effects model revealed that the least-squares geometric mean ratios of area under the concentration-time curve (AUC)0-t , AUC0-∞ and maximum plasma concentration (Cmax, 90% confidence intervals) of pyrotinib alone and pyrotinib coadministered with omeprazole were 0.94 (0.82, 1.08), 0.94 (0.83, 1.08) and 0.91 (0.806, 1.038), respectively, indicating the absence of significant differences in AUC0-t , AUC0-∞ and Cmax . During the treatment period, 6 subjects (33.3%) reported 8 adverse events during pyrotinib monotherapy and omeprazole administration, respectively; 10 subjects (55.6%) reported 34 adverse events in the combined administration phase. CONCLUSION: Omeprazole, a proton-pump inhibitor, did not significantly impact the PK properties of pyrotinib, and a good safety profile was observed on coadministration.
引用
- Li X, Wang Y, Zhu X, et al. Clinical study of drug-drug interaction between omeprazole and pyrotinib after meal. Br J Clin Pharmacol. 2021. PMID: 34873745. doi:10.1111/bcp.15169
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。